Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed and active Waldenstrom's Macroglobulinemia requiring treatment.~* Ambulatory and capable of all selfcare. Up and about more than 50% of waking hours.~* Adequate organ function.~* Detectable CD20 positive of the tumor cells.~* Measurable disease as defined by a monoclonal IgM paraprotein level greater than 1000 mg/dL.~Exclusion Criteria:~* Treatment of WM within the past 28 days.~* Treatment with rituximab or alemtuzamab within the past 3 months.~* Certain heart problems, chronic or current active infection not controlled with oral antibiotics, other current cancer or within last 5 years.~* Current participation in another interventional clinical study.~* Lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception.~* Active cerebrovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab (Type: EXPERIMENTAL): Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).